Can the CSL share price really reach $500 in just 3 years?

Leading analysts are expecting big returns from CSL shares in the months ahead.

| More on:
woman in lab coat conducting testing representing biotech

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Ltd (ASX: CSL) share price is up 1.3% in afternoon trade today.

Shares in the S&P/ASX 200 Index (ASX: XJO) biotech stock closed yesterday trading for $280.08. At time of writing on Wednesday, shares are swapping hands for $283.60 apiece.

As you can see on the chart below, that leaves the biotech stock down around 6% since this time last year.

As you can also see, CSL enjoyed a big rebound at the end of October, with shares up more than 22% since 31 October.

But for the CSL share price to hit $500 it would need to gain another 79% from current levels.

Is that achievable in just three years?

According to the analysts at Macquarie, it most certainly is.

Why the CSL share price could soar from here

As a bit of background, CSL has three operating arms: CSL Behring (the company's blood plasma segment), CSL Vifor, and its Seqirus businesses.

The company acquired CSL Vifor, a global leader in iron deficiency therapies, in 2022 for US$11.7 billion.

While Vifor has been struggling to achieve growth since that acquisition, it's the Behring division that Macquarie believes could help propel the CSL share price to new heights.

As The Australian Financial Review reports, Macquarie's analysts believe the biotech giant is trading significantly below its 10-year average price-to-earnings (P/E) ratio. Macquarie expects CSL to trade back at historic P/E ratios amid annual earnings growth of some 15%.

That's based expectations that CSL Behring will make up 90% of that earnings growth over the next five years.

As for the CSL share price hitting $500 in three years, the analysts said, "We see this as both attractive and achievable."

Indeed, when CSL reported its half-year results on 13 February, CEO Paul McKenzie said:

For FY 2024, I am pleased to reaffirm our previous guidance. CSL's underlying profit, NPATA is expected to be in the range of approximately $2.9 billion to $3.0 billion at constant currency, representing growth over FY23 of approximately 13% to 17%.

Scott Olsson, a portfolio manager at Firetrail Investments' Australian high conviction fund, which owns CSL stock, is also bullish on the outlook for the CSL share price, citing a pullback in the high costs encountered during the pandemic alongside an improved outlook for the company's plasma collections.

According to Olsson (quoted by the AFR):

We think CSL presents a buying opportunity now because the market is more sceptical on management than it has been in the past, and the Vifor acquisition is turning out to not be a great buy so far, but that's a very small part of the business. I think the market is quite distracted on a few things."

What are other experts saying?

Atop Macquarie and Firetrail, a number of other investment experts are bullish on the outlook for the CSL share price.

As the Motley Fool reported yesterday, Morgans has an 'add' rating and $315.40 price target on the ASX 200 biotech stock's shares.

The analysts at UBS recently gave CSL the equivalent of a 'buy' rating, with a $330.00 price target.

Now, these are 12-month price targets, mind you, while Macquarie's $500 a share forecast for CSL is a three-year prediction.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two lab workers fist pump each other.
Healthcare Shares

3 reasons to buy CSL shares today

Two investment experts expect a big turnaround for CSL shares in 2025.

Read more »

Business people discussing project on digital tablet.
Healthcare Shares

Down 4%, is the ResMed share price in the buy zone?

Do analysts think investors should be buying the dip? Let's see what they are saying.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Guess which ASX 100 share is sinking 8% because of Trump's tariffs

Donald Trump has dealt this company a big blow. What's happening?

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Up 1,090% in a year, why is the Mesoblast share price leaping higher again on Friday?

Mesoblast shares have surged more than 1,000% over the last 12 months.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Earnings Results

ResMed shares rise on strong Q2 result

Let's see how this sleep treatment company performed during the second quarter.

Read more »

Person holding Australian dollar notes, symbolising dividends.
Healthcare Shares

$1,000 invested in Mesoblast shares at the start of 2024 is now worth…

Did this biotech company deliver the goods for investors? Let's see what a $1,000 investment would be worth.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Sigma share price drops after shareholders vote on Chemist Warehouse merger

The results are in.

Read more »

Man with his hand out the front, symbolising a trading halt.
Healthcare Shares

Halted: What's going on with Sigma shares today?

Sigma investors would be holding their breath right now.

Read more »